Dr. Chapa’s OBGYN Clinical Pearls

Episode: What’s Best Analgesia for ECV?
Date: March 16, 2026
Host: Dr. Chapa

Episode Overview

In this clinical, evidence-based episode, Dr. Chapa dives deep into the best pain relief options for External Cephalic Version (ECV), focusing particularly on the latest data comparing epidural anesthesia against intravenous (IV) remifentanil and stepwise approaches. Recent research published in March 2026 is reviewed, with practical recommendations for clinicians counseling patients facing a breech presentation and considering ECV.

Key Discussion Points & Insights

1. The Decline of Vaginal Breech Delivery and Rise of ECV

• Dr. Chapa opens humorously reflecting on his own breech birth, relating it to the clinical challenge of breech presentations.
• Emphasizes that while vaginal breech delivery is now rare (due to skill loss and safety concerns), ECV is a critical intervention to avoid cesarean and promote vaginal birth.

2. ECV: What Does ACOG Recommend? [06:05]

• Practice Bulletin Recap:
  • ACOG Practice Bulletin 221 highlights neuraxial analgesia (epidural or spinal) paired with a tocolytic as increasing ECV success.
  • No clear evidence that one is superior, but clinical practice often favors epidural due to its flexibility and longer duration.
  • "Without question, neuroaxial anesthesia plus a tocolytic agent increases success and makes the procedure much more tolerable." [06:44]

3. Understanding Remifentanil as Analgesia [07:46]

• Remifentanil Overview:

  • Synthetic, ultra-short-acting μ-opioid agonist used for potent pain relief.
  • Fast onset/offset; administered IV, often by PCA.
  • Metabolism: By plasma esterases—not liver, making for rapid clearance.
  • Risks: Respiratory depression is the main danger, highlighting need for oxygen monitoring and adherence to protocols.
  • "Remifentanil, when used in the correct way is phenomenal, despite the FDA warning..." [07:59]

• FDA Label vs. Clinical Practice:

  • FDA label warns against intrapartum use, but clinical data supports safety with proper safeguards.
  • Noted disconnect between real-world outcomes and regulatory caution, similar to other obstetric medications (e.g., misoprostol).

4. Key Evidence Supporting Remifentanil for Labor Analgesia (Prior Trials) [11:50]

• RESPITE Trial (Lancet, 2018):

  • 400+ women; remifentanil PCA reduced need for epidural and need to switch agents.
  • Lower rates of instrumental vaginal delivery (forceps/vacuum) vs. epidural.

• Cochrane Review (2017):

  • Meta-analysis of 20 RCTs (3500+ women): Remifentanil superior to other IV opioids.
  • 50% reduction in need to escalate pain control compared to alternatives.

5. The New Spanish (Espana) Study—2026 AJOG Publication [14:40]

• Design:

  • Single-center, prospective cohort over 12 years (2012-2024), nearly 2,000 singleton pregnancies undergoing ECV.
  • Three consecutive cohorts:
    • Group 1: IV Remifentanil (2012-2015)
    • Group 2: Stepwise (IV Remi, then epidural if Remi failed) (2016-2019)
    • Group 3: Epidural anesthesia (2020-2024)
  • All used standardized ECV protocol; tocolysis with ridadrine or atosaban (reflecting European setting).

• Findings:

  • Epidural Wins:

    • Success Rates: Highest with epidural—~70% successful version rate.
    • Pain Control: 78% of women with epidural reported “no or minimal pain” vs. 49% in Remifentanil group.
    • Vaginal Delivery Rates: Increased in epidural cohort.
    • Downside: More maternal hypotension/dizziness, but not associated with serious clinical consequences.

  • Notable Quote:
    "Epidural wins, epidural wins. Success rates were highest with the epidural at about 70% compared with IV remifentanil or the stepwise progressive approach." [17:51]

  • Counseling Point:
    Women should be informed that epidural offers best overall success and pain relief but with a small risk of hypotension.

6. Broader Literature and Meta-Analysis [21:50]

• 2020 Network Meta-Analysis (Anesthesia & Analgesia):
  • Compared IV sedation, inhalational analgesia, and neuraxial techniques.
  • Neuraxial (Epidural/Spinal) had the highest odds of success:
    “Odds ratio of 2.59 compared to IV sedation... nitronox had odds ratio 2.3.” [21:51]
  • Conclusion: Epidural > IV sedation > inhaled agents for successful ECV and pain control.

7. How To Apply This At The Bedside [21:50]

• Routine counseling at 36 weeks for breech: Offer ECV if eligible.

• Clearly explain analgesia options and success rates.

  • “We want to give you an epidural. We’re going to give you a little shot called terbutaline... and give it the old college try.” [22:13]

• IV Remifentanil remains a valid alternative for those who decline neuraxial analgesia, provided consent and monitoring protocols are strict.

• Clinical Bottom Line:

  • Epidural plus tocolytic remains the gold standard for pain relief and success in ECV, supported across guidelines and new research.

Notable Quotes & Memorable Moments

• “Neuraxial anesthesia of some flavor. Although most people do an epidural... is the pain control method that best increases the success rate for ECV.”
  — Dr. Chapa [02:02]

• “Remifentanil, when used in the correct way is phenomenal, despite the FDA warning...”
  — Dr. Chapa [07:59]

• “Epidural wins. Success rates were highest with the epidural at about 70% compared with IV remifentanil or the stepwise approach.”
  — Dr. Chapa [17:51]

• “Maternal pain was also much better controlled with the epidural, with 78% of women reporting no or minimal pain, whereas it was 49% in the REMI group.”
  — Dr. Chapa [18:30]

• “Neuraxial anesthesia has significantly higher odds of successful version with an odds ratio of 2.59 compared to IV sedation...”
  — Dr. Chapa citing meta-analysis [21:51]

Timestamps for Key Segments

• [02:02] — Overview of Neuraxial Anesthesia for ECV, ACOG guidance
• [06:05] — ACOG's Practice Bulletin 221 recommendations
• [07:46] — Remifentanil: mechanism, risks, use in labor wards
• [11:50] — RESPITE trial & Cochrane review (remifentanil for labor pain)
• [14:40] — New Spanish Study Design (2026 AJOG publication)
• [17:51] — Results: Epidural outperforms IV Remi/stepwise
• [18:30] — Maternal pain and delivery outcomes
• [21:51] — 2020 meta-analysis supports neuraxial over other analgesia
• [22:13] — Practical counseling for ECV in clinical practice

Clinical Takeaway

• Best Analgesia for ECV: Epidural anesthesia plus a tocolytic agent provides the best chance for successful version, optimal pain control, and higher vaginal birth rates—with only minor, manageable risks.
• Alternatives: IV remifentanil is safe and effective with strict adherence to safety protocols and proper patient consent, but does not outperform epidural.
• Guideline Alignment: New data from Spain and meta-analyses reinforce ACOG recommendations.

Tone:
Down-to-earth, practical, often humorous, and always directed at empowering clinicians with up-to-date, actionable information.

Summary Prepared For:
Providers who haven't listened, need a rapid but thorough update on ECV pain control backed by the very latest evidence and guideline consensus.